Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss First Quarter 2016 Financial Results
(firmenpresse) - THE WOODLANDS, TX -- (Marketwired) -- 05/10/16 -- (NASDAQ: OPXA), a company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that the Company will report financial results for the quarter ended March 31, 2016 after the close of trading on Thursday, May 12th. The Company will also conduct a conference call and webcast to discuss financial results and provide a corporate update at 4:30 P.M. ET on Thursday, May 12th.
To listen to the 4:30 P.M. conference call, dial 201-689-8040 or toll free 877-407-8133. The conference ID number is 13636799.
A live webcast of the call can also be accessed or via the webcast link on the Investor Relations page of Opexa''s website (). An archive of the webcast will be available on the Company''s website until August 12, 2016.
There will be a brief Question & Answer session following management commentary.
Opexa is a biopharmaceutical company developing personalized immunotherapies with the potential to treat major illnesses, including multiple sclerosis (MS) as well as other autoimmune diseases such as neuromyelitis optica (NMO). These therapies are based on Opexa''s proprietary T-cell technology. The Company''s leading therapy candidate, Tcelna®, is a personalized T-cell immunotherapy that is in a Phase IIb clinical development program (the Abili-T trial) for the treatment of secondary progressive MS. Tcelna consists of myelin-reactive T-cells, which are expanded ex vivo from the patient''s peripheral blood and reintroduced into the same patient in an attenuated form via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin for each individual patient. Top-line results from the Abili-T trial are expected in early 4th quarter of 2016.
For more information, visit the Opexa Therapeutics website at or follow company news on Twitter via .
Opexa Therapeutics, Inc.
Camilla Zuckero
281.775.0609
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 10.05.2016 - 07:00 Uhr
Sprache: Deutsch
News-ID 1433903
Anzahl Zeichen: 3217
contact information:
Contact person:
Town:
THE WOODLANDS, TX
Phone:
Kategorie:
Alternative
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 189 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss First Quarter 2016 Financial Results
"
steht unter der journalistisch-redaktionellen Verantwortung von
Opexa Therapeutics, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
